The agenda for the special out-of-session Pharmaceutical Benefits Advisory Committee (PBAC) meeting is available on the PBS website.
At this meeting, to be held on 30 July 2026, the PBAC will consider a request to change the existing PBS listing for triptorelin 3.75 mg intramuscular injection to support its use across a number of women’s health conditions.
The PBAC has already received a significant number of clinical and consumer inputs from a range of organisations and individuals in relation to this matter. Given the timing of the meeting, further public consultation will not be possible to be undertaken.
Outcomes from the meeting will be published on the PBS website.